GIA
FLNA

GHP Investment Advisors’s Filana Therapeutics FLNA Stock Holding History

GHP Investment Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$25 – 1064
2024
Q2 		$25 Buy
+2
New +$42 ﹤0.01% 965

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TI
Tidal Investments Milwaukee, Wisconsin $47.4B AUM 59.58% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GHP Investment Advisors's FLNA Position: Q3 2024 in Review

GHP Investment Advisors sold out of Filana Therapeutics (FLNA) in Q3 2024, closing a stake of 2 shares — an estimated $25 sold.

GHP Investment Advisors first reported a position in FLNA in Q2 2024 and held it in 1 quarter. The position peaked at $25 in Q2 2024. 161 funds tracked by Wall St. Rank hold FLNA as of Q3 2024.

  • GHP Investment Advisors reported no remaining Filana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • GHP Investment Advisors sold 2 Filana Therapeutics shares in Q3 2024, an estimated $25.
  • GHP Investment Advisors first reported a position in Filana Therapeutics in Q2 2024 and held it in 1 quarter.
  • GHP Investment Advisors's Filana Therapeutics position peaked at $25 in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2024.

Based on GHP Investment Advisors's 13F filing for Q3 2024, filed 24 Oct 2024.